Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer

Dylan P. McClurg; Gordan Urquhart; Trevor McGoldrick; Subarnarekha Chatterji; Zosia Miedzybrodzka; Valerie Speirs; Beatrix Elsberger

doi:10.3390/cancers14133175

Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer

Dylan P. McClurg, Gordan Urquhart, Trevor McGoldrick, Subarnarekha Chatterji, Zosia Miedzybrodzka, Valerie Speirs^* (Corresponding Author), Beatrix Elsberger^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

5 Downloads (Pure)

Abstract

Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all breast cancers and male malignancies. Despite recognised clinico-pathological and molecular differences to female breast cancer (FBC), the clinical management of MBC follows established FBC treatment strategies. Loss of function mutations in the DNA damage response genes BRCA1 and BRCA2, have been strongly implicated in the pathogenesis of MBC. While there have been extensive clinical advancements in other BRCA-related malignancies, including FBC, improvements in MBC remain stagnant. Here we present a review that highlights the lack of treatment evidence for BRCA-related MBC and the required national and global collaborative effort to address this unmet need. In doing so, we summarise the transformative clinical advancements with poly(ADP-ribose) polymerase (PARP) inhibitors in other BRCA-related cancers namely, FBC and prostate cancer.

Original language	English
Article number	3175
Number of pages	17
Journal	Cancers
Volume	14
Issue number	13
Early online date	28 Jun 2022
DOIs	https://doi.org/10.3390/cancers14133175
Publication status	Published - 28 Jun 2022

Bibliographical note

Funding: This research was funded by The University of Aberdeen Development Trust, Breast Cancer UK and NHS Grampian Breast Cancer Endowment Fund. S.C. is in receipt of an Elphinstone Scholarship.

Keywords

male breast cancer
BRCA
clinical management
PARP inhibitors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers14133175Licence: CC BY

McClurg_etal_C_Analysis_Of_The_VoR
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Final published version, 379 KBLicence: CC BY

Cite this

@article{047842434486494da1aa7ce76c91b225,

title = "Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer",

abstract = "Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all breast cancers and male malignancies. Despite recognised clinico-pathological and molecular differences to female breast cancer (FBC), the clinical management of MBC follows established FBC treatment strategies. Loss of function mutations in the DNA damage response genes BRCA1 and BRCA2, have been strongly implicated in the pathogenesis of MBC. While there have been extensive clinical advancements in other BRCA-related malignancies, including FBC, improvements in MBC remain stagnant. Here we present a review that highlights the lack of treatment evidence for BRCA-related MBC and the required national and global collaborative effort to address this unmet need. In doing so, we summarise the transformative clinical advancements with poly(ADP-ribose) polymerase (PARP) inhibitors in other BRCA-related cancers namely, FBC and prostate cancer.",

keywords = "male breast cancer, BRCA, clinical management, PARP inhibitors",

author = "McClurg, {Dylan P.} and Gordan Urquhart and Trevor McGoldrick and Subarnarekha Chatterji and Zosia Miedzybrodzka and Valerie Speirs and Beatrix Elsberger",

note = "Funding: This research was funded by The University of Aberdeen Development Trust, Breast Cancer UK and NHS Grampian Breast Cancer Endowment Fund. S.C. is in receipt of an Elphinstone Scholarship.",

year = "2022",

month = jun,

day = "28",

doi = "10.3390/cancers14133175",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "13",

}

TY - JOUR

T1 - Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer

AU - McClurg, Dylan P.

AU - Urquhart, Gordan

AU - McGoldrick, Trevor

AU - Chatterji, Subarnarekha

AU - Miedzybrodzka, Zosia

AU - Speirs, Valerie

AU - Elsberger, Beatrix

N1 - Funding: This research was funded by The University of Aberdeen Development Trust, Breast Cancer UK and NHS Grampian Breast Cancer Endowment Fund. S.C. is in receipt of an Elphinstone Scholarship.

PY - 2022/6/28

Y1 - 2022/6/28

N2 - Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all breast cancers and male malignancies. Despite recognised clinico-pathological and molecular differences to female breast cancer (FBC), the clinical management of MBC follows established FBC treatment strategies. Loss of function mutations in the DNA damage response genes BRCA1 and BRCA2, have been strongly implicated in the pathogenesis of MBC. While there have been extensive clinical advancements in other BRCA-related malignancies, including FBC, improvements in MBC remain stagnant. Here we present a review that highlights the lack of treatment evidence for BRCA-related MBC and the required national and global collaborative effort to address this unmet need. In doing so, we summarise the transformative clinical advancements with poly(ADP-ribose) polymerase (PARP) inhibitors in other BRCA-related cancers namely, FBC and prostate cancer.

AB - Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all breast cancers and male malignancies. Despite recognised clinico-pathological and molecular differences to female breast cancer (FBC), the clinical management of MBC follows established FBC treatment strategies. Loss of function mutations in the DNA damage response genes BRCA1 and BRCA2, have been strongly implicated in the pathogenesis of MBC. While there have been extensive clinical advancements in other BRCA-related malignancies, including FBC, improvements in MBC remain stagnant. Here we present a review that highlights the lack of treatment evidence for BRCA-related MBC and the required national and global collaborative effort to address this unmet need. In doing so, we summarise the transformative clinical advancements with poly(ADP-ribose) polymerase (PARP) inhibitors in other BRCA-related cancers namely, FBC and prostate cancer.

KW - male breast cancer

KW - BRCA

KW - clinical management

KW - PARP inhibitors

U2 - 10.3390/cancers14133175

DO - 10.3390/cancers14133175

M3 - Article

C2 - 35804947

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 13

M1 - 3175

ER -

Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this